These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11603901)

  • 1. ESPRIT in context: pharmacology matters!
    Tcheng JE; Strony J; Lorenz TJ; O'Shea JC
    Eur Heart J; 2001 Nov; 22(21):1965-7. PubMed ID: 11603901
    [No Abstract]   [Full Text] [Related]  

  • 2. Duration of action of GpIIb-IIIa antagonists.
    Johnson K
    Crit Care Nurse; 2000 Oct; 20(5):16. PubMed ID: 11878484
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract]   [Full Text] [Related]  

  • 4. [GPIIb/IIIa inhibitor].
    Ikeda Y
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1174-81. PubMed ID: 10771692
    [No Abstract]   [Full Text] [Related]  

  • 5. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microcirculatory effects of abciximab and eptifibatide: a critical appraisal.
    Kereiakes DJ
    J Invasive Cardiol; 2003 Sep; 15(9):481-3. PubMed ID: 12947205
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time.
    Levy JH; Kelley A
    Circulation; 1997 Nov; 96(10):3793-4. PubMed ID: 9396497
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Melandri G
    Lancet; 2001 Dec; 358(9297):1997. PubMed ID: 11747953
    [No Abstract]   [Full Text] [Related]  

  • 12. [Glycoprotein IIb/IIIa receptor inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1996 Dec; 19(12):356-8. PubMed ID: 9082150
    [No Abstract]   [Full Text] [Related]  

  • 13. [Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists].
    Kondo K
    Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):263-8. PubMed ID: 11215375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of GP IIb/IIIa blockers in clinical cardiology].
    Rossi ML; Merlini PA
    Recenti Prog Med; 2003 Oct; 94(10):440-3. PubMed ID: 14619191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
    Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S; Tamura N; Ishida H
    J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What have We learned from ESPRIT? What will we learn from TARGET?
    Ferguson JJ
    J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.